Protease inhibitors and urolithiasis

Journal of Urology

Volumn 158, Issue 1, 1997, Pages 31-33

  Sutherland, Suzette E ^a   Reigle, Melissa D ^a   Seftel, Allen D ^a,b   Resnick, Martin I ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Human immunodeficiency virus; Protease inhibitors; Urinary calculi

Indexed keywords

ACICLOVIR; ASCORBIC ACID; CLARITHROMYCIN; COTRIMOXAZOLE; GANCICLOVIR; INDINAVIR; LAMIVUDINE; LORATADINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ADULT; ANOREXIA; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG ACCUMULATION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; TASTE DISORDER; UROLITHIASIS; VOMITING;

EID: 0030980876     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199707000-00007     Document Type: Article

References (25)

1. Deutsch, P., Teppler, H. and Squires, K.: Antiviral activity of L735-524, an HIV protease inhibitor, in infected patients. Read at Interscience Conference on Antimicrobial Agents and Chemotherapy, Florida, p. 159, 1994.
2. Stein, D. S., Fish, D. G. and Chodakewitz, J.: A 24 week open label phase I evaluation of the HIV protease inhibitor L735-524. Read at National Conference on Human Retroviruses and Related Infections, Washington, D.C., 1995.
3. 3. Read at National Conference on Human Retroviruses and Related Infections, Washington, D.C., p. 183, 1995.
4. Winslow, D. L. and Otto, M. J.: HIV protease inhibitors. AIDS, suppl. A, 9: S183, 1995
5. Chodakewitz, J., Deutsch, P. and Leavitt, R.: Preliminary evaluation of the long term safety & antiviral activity exerted by CRIXIVAN (MK-639), an oral HIV protease inhibitor. Read at European Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen, p. 7, 1995.
6. Gulick, T., Mellors, J. and Havlur, D.: Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ADV) and lamivudine (3TC). Read at Conference on Retroviruses and Opportunistic Infections, Washington, D.C., p. 162, 1996.
7. Massari, F., Stazewski, S. and Berry, P.: A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs. zidovudine alone in zidovudine-naive patients. Read at Interscience Conference on Antimicrobial Agents and Chemotherapy, California, 1995.
8. 3. Read at Interscience Conference on Antimicrobial Agents and Chemotherapy, California, p. 235, 1995.
9. McQuade, T. J., Tomasselli, A. G., Liu, L., Karacostas, V., Moss, B., Sawyer, T. K., Heinrikson, R. L. and Tarpley, W. G.: A synthetic HIV protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science, 247: 454, 1990.
10. Champoux, J. J.: Retroviruses, Medical Microbiology: An Introduction to Infectious Diseases, 2nd ed. Edited by J. C. Sherris. Connecticut: Appleton & Lange, pp. 603-611, 1990.
11. Ashorn, P., McQuade, T. J., Thaisrivongs, S., Tomasselli, A. G., Tarpley, W. G. and Moss, B.: An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc. Nat. Acad. Sci., 87: 7472, 1990.
12. Craig, J. C., Duncan, I. B., Whittaker, L. and Roberts, M. A.: Antiviral synergy between inhibitors of HIV proteinase and reverse transcriptase. Antiviral Chem. Chemother., 4: 161, 1993.
13. Kaplan, A. H. and Swanstrom, R.: The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity. Biomed. Biochem. Acta, 50: 647, 1991.
14. Shoeman, R. L., Honer, B., Stoller, T. J., Kesselmeier, C., Miedel, M. C., Traub, P. and Graves, M. C.: Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc. Nat. Acad. Sci., 87: 6336, 1990.
15. Adams, L. D., Tomasselli, A. G., Robbins, P., Moss, B. and Heinrikson, R. L.: HIV-1 protease cleaves actin during acute infection of human T-lymphocytes. AIDS Res. Hum. Retroviruses, 8: 291, 1992.
16. Oswald, M. and Von der Helm, K.: Fibromectin is a non-viral substrate for the HIV proteinase. FEBS Bull., 292: 298, 1991.
17. Tomasselli, A. G., Howe, W. J., Hui, J. O., Sawyer, T. K., Reardon, J. M., DeCamp, D. L., Craik, C. S. and Heinrikson, R. L.: Calcium-free calmodulin is a substrate of proteases from human immunodeficiency viruses 1 and 2. Proteins, 10: 1, 1991.
18. Perno, C. F., Bergamini, A., Pesce, C. D., Milanese, G., Capozzi, M. Aquaro, S., Thaisrivongs, S., Tarpley, W. G., Zon, G. and D'Agostini, C.: Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J. Infect. Dis., 168: 1148, 1993.
19. Coe, F. L. and Favus, M. J.: Nephrolithiasis. In: Harrison's Principles of Internal Medicine, 13th ed. Edited by K. J. Isselvacher, E. Braunwald, J. D. Wilson, J. B. Martin, A. S. Fauci and D. L. Kasper. New York: McGraw-Hill Book Co., pp. 1329-1333, 1994.
20. New drugs for HIV infection. Med. Lett. Drugs Ther., 38: 35, 1996.
21. Vella, S.: Clinical experience with saquinavir. AIDS, suppl 2, 9: S21, 1995.
22. Muirhead, G. J., Shaw, T., Williams, P. E. O., et al.: Pharmacokinetics of the HIV-proteinase inhibitor Ro 31-8959 after single and multiple oral doses in healthy volunteers. Brit. J. Clin. Pharmacol., 34: 170, 1992.
23. Roberts, N. A.: Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS, suppl 2, 9: S27, 1995.
24. Norbeck, D., Kumar, G. and Marsh, K.: Ritonavir and saquinavir: potential for two-dimensional synergy between HIV protease inhibitors. Read at Interscience Conference on Antimicrobial Agents and Chemotherapy, California, 1995.
25. Update: Provisional Public Health service recommendations for chemoprophylaxis after occupational-exposure to HIV. Morbid. Mortal. Weekly Rep., 45: 468, 1996.